Pale Fire Capital SE Grows Stake in Fractyl Health, Inc. $GUTS

Pale Fire Capital SE raised its position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) by 84.5% in the first quarter, Holdings Channel.com reports. The fund owned 5,921,045 shares of the company’s stock after acquiring an additional 2,711,103 shares during the quarter. Fractyl Health makes up approximately 0.2% of Pale Fire Capital SE’s portfolio, making the stock its 24th biggest holding. Pale Fire Capital SE’s holdings in Fractyl Health were worth $2,711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in GUTS. Jane Street Group LLC acquired a new stake in Fractyl Health during the second quarter worth about $31,000. Jump Financial LLC purchased a new stake in Fractyl Health during the 4th quarter worth about $57,000. Scientech Research LLC acquired a new stake in Fractyl Health in the third quarter valued at approximately $49,000. Prelude Capital Management LLC acquired a new position in shares of Fractyl Health during the third quarter worth $55,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Fractyl Health during the 4th quarter worth about $85,000.

Insider Activity

In other news, Director William Bradley acquired 68,493 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average price of $0.73 per share, with a total value of $49,999.89. Following the completion of the transaction, the director directly owned 84,622 shares in the company, valued at approximately $61,774.06. This represents a 424.66% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ian Sheffield bought 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the transaction, the director owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 171,493 shares of company stock valued at $127,150 in the last three months. 8.52% of the stock is currently owned by corporate insiders.

Fractyl Health Trading Up 2.2%

Shares of Fractyl Health stock opened at $0.77 on Friday. The company’s fifty day moving average is $0.80 and its two-hundred day moving average is $0.81. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The company has a market capitalization of $122.64 million, a P/E ratio of -0.60 and a beta of 2.29. Fractyl Health, Inc. has a 1 year low of $0.38 and a 1 year high of $2.44.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. Analysts forecast that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on GUTS shares. Craig Hallum began coverage on shares of Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 target price for the company. Weiss Ratings raised shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.12.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.